Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-PSMA chimeric antigen receptor T cell therapy - BRL Medicine

Next Previous
Drug Profile

Anti-PSMA chimeric antigen receptor T cell therapy - BRL Medicine

Alternative Names: Anti-prostate specific membrane antigen CAR T cell therapy - BRL Medicine; Anti-PSMA CAR T cell therapy - BRL Medicine; Autologous PSMA-specific chimeric antigen receptor T cell therapy - BRL Medicine; PSMA-CAT T cell therapy

Latest Information Update: 05 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Bioray Laboratory
  • Developer BRL Medicine
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 29 Jan 2024 Shanghai Changzheng Hospital in collaboration with Bioray Laboratories initiates a phase 0 trial for Prostate cancer (Metastatic disease, Second-line therapy or greater, Hormone refractory) in China (NCT06228404)
  • 11 Apr 2022 Shanghai Bioray Laboratories suspends a phase I/II trial in Prostate cancer (Metastatic disease, Hormone refractory) in China (IV), due to efficacy evaluation (NCT04053062)
  • 08 Aug 2019 Phase-I/II clinical trials in Prostate cancer (Metastatic disease, Hormone refractory) in China (IV) (NCT04053062)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top